IBD1
MCID: INF071
MIFTS: 51

Inflammatory Bowel Disease 1 (IBD1) malady

Categories: Genetic diseases, Gastrointestinal diseases, Rare diseases, Bone diseases, Blood diseases, Immune diseases

Aliases & Classifications for Inflammatory Bowel Disease 1

Aliases & Descriptions for Inflammatory Bowel Disease 1:

Name: Inflammatory Bowel Disease 1 54 12 66 14
Crohn Disease-Associated Growth Failure 54 66 13
Inflammatory Bowel Disease 1 66 29
Ulcerative Colitis 66 69
Regional Enteritis 66 69
Crohn Disease 66 69
Ibd1 12 66

Characteristics:

HPO:

32
inflammatory bowel disease 1:
Inheritance heterogeneous multifactorial inheritance


Classifications:



External Ids:

OMIM 54 266600
Disease Ontology 12 DOID:0110892

Summaries for Inflammatory Bowel Disease 1

UniProtKB/Swiss-Prot : 66 Inflammatory bowel disease 1: A chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints.

MalaCards based summary : Inflammatory Bowel Disease 1, also known as crohn disease-associated growth failure, is related to crohn's colitis and ulcerative colitis, and has symptoms including abdominal pain, diarrhea and weight loss. An important gene associated with Inflammatory Bowel Disease 1 is NOD2 (Nucleotide Binding Oligomerization Domain Containing 2), and among its related pathways/superpathways are Pertussis and Shigellosis. The drugs Adalimumab and Infliximab have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and colon.

Disease Ontology : 12 An inflammatory bowel disease that has material basis in mutations in the NOD2 gene on chromosome 16q12.1.

Description from OMIM: 266600

Related Diseases for Inflammatory Bowel Disease 1

Diseases in the Inflammatory Bowel Disease family:

Inflammatory Bowel Disease 7 Inflammatory Bowel Disease 23
Inflammatory Bowel Disease 10 Inflammatory Bowel Disease 9
Inflammatory Bowel Disease 12 Inflammatory Bowel Disease 18
Inflammatory Bowel Disease 5 Inflammatory Bowel Disease 19
Inflammatory Bowel Disease 3 Inflammatory Bowel Disease 13
Inflammatory Bowel Disease 11 Inflammatory Bowel Disease 14
Inflammatory Bowel Disease 16 Inflammatory Bowel Disease 15
Inflammatory Bowel Disease 20 Inflammatory Bowel Disease 28, Early Onset, Autosomal Recessive
Inflammatory Bowel Disease 2 Inflammatory Bowel Disease 26
Inflammatory Bowel Disease 27 Inflammatory Bowel Disease 4
Inflammatory Bowel Disease 8 Inflammatory Bowel Disease 1
Inflammatory Bowel Disease 22 Inflammatory Bowel Disease 21
Inflammatory Bowel Disease 6 Inflammatory Bowel Disease 24
Inflammatory Bowel Disease 25, Early Onset, Autosomal Recessive Il21-Related Infantile Inflammatory Bowel Disease

Diseases related to Inflammatory Bowel Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 33)
id Related Disease Score Top Affiliating Genes
1 crohn's colitis 31.8 IL6 NOD2
2 ulcerative colitis 12.7
3 pediatric ulcerative colitis 12.2
4 crohn's disease 11.8
5 ulcerative proctitis 11.4
6 inflammatory bowel disease 13 10.8
7 inflammatory bowel disease 14 10.8
8 inflammatory bowel disease 28, early onset, autosomal recessive 10.8
9 inflammatory bowel disease 25, early onset, autosomal recessive 10.8
10 inflammatory bowel disease 17, protection against 10.8
11 inflammatory bowel disease 10 10.8
12 inflammatory bowel disease 19 10.8
13 hypomagnesemia 1, intestinal 10.7
14 autoimmune disease 6 10.7
15 bile acid malabsorption, primary 10.7
16 6-mercaptopurine sensitivity 10.7
17 multiple sulfatase deficiency 10.1 NOD1 NOD2
18 x inactivation, familial skewed, 2 10.1 NOD1 NOD2
19 microphthalmia, isolated 7 10.1 HOGA1 NOD2
20 parkinson disease 11 10.0 NOD1 NOD2
21 spastic paraplegia 3a, autosomal dominant 10.0 HOGA1 NOD2
22 meier-gorlin syndrome 3 10.0 NOD1 NOD2
23 paragonimiasis 10.0 IL6 NOD2
24 premature menopause 10.0 IL6 NOD2
25 pseudohypoaldosteronism, type iid 10.0 NOD2 SLC22A5
26 inflammatory bowel disease 10.0
27 jejunoileitis 9.9
28 gastroduodenal crohn's disease 9.9
29 colitis 9.9
30 psoriatic arthritis 9.9 HOGA1 NOD1 NOD2
31 glycogen storage disease ix 9.8 IGSF6 IL6 NOD1 NOD2
32 dengue disease 9.6 IL6 NOD1 NOD2 SLC22A5
33 sarcoidosis, early-onset 8.9 HOGA1 IGSF6 IGSF6-DREV1 IL6 METTL9 NOD1

Comorbidity relations with Inflammatory Bowel Disease 1 via Phenotypic Disease Network (PDN): (show all 11)


Active Peptic Ulcer Disease Acute Cystitis
Crohn's Disease Deficiency Anemia
Esophagitis Intestinal Obstruction
Iron Deficiency Anemia Osteoporosis
Paralytic Ileus Protein-Energy Malnutrition
Ulcerative Colitis

Graphical network of the top 20 diseases related to Inflammatory Bowel Disease 1:



Diseases related to Inflammatory Bowel Disease 1

Symptoms & Phenotypes for Inflammatory Bowel Disease 1

Symptoms by clinical synopsis from OMIM:

266600

Clinical features from OMIM:

266600

Human phenotypes related to Inflammatory Bowel Disease 1:

32 (show all 7)
id Description HPO Frequency HPO Source Accession
1 abdominal pain 32 HP:0002027
2 diarrhea 32 HP:0002014
3 weight loss 32 HP:0001824
4 growth delay 32 HP:0001510
5 intestinal obstruction 32 HP:0005214
6 recurrent aphthous stomatitis 32 HP:0011107
7 ulcerative colitis 32 HP:0100279

UMLS symptoms related to Inflammatory Bowel Disease 1:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

Drugs & Therapeutics for Inflammatory Bowel Disease 1

Drugs for Inflammatory Bowel Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 721)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1 331731-18-1 16219006
2
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1 170277-31-3
3
Clarithromycin Approved Phase 4,Phase 3,Phase 1 81103-11-9 84029
4
Clofazimine Approved, Investigational Phase 4,Phase 3 2030-63-9 2794
5
Rifabutin Approved Phase 4,Phase 3 72559-06-9 6323490
6
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
8
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-23-7 5754 657311
9
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 53-03-2 5865
10
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 1994-09-7, 94-09-7 2337
11
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1 428863-50-7
12
Sulfamethazine Approved, Vet_approved Phase 4 57-68-1 5327
13
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-78-2 2244
14
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 80621-81-4 6436173
15
Sucralfate Approved Phase 4 54182-58-0
16
Celecoxib Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 169590-42-5 2662
17 Parecoxib Approved Phase 4 198470-84-7
18
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
19
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1 446-86-6 2265
20
Budesonide Approved Phase 4,Phase 3,Phase 2,Phase 1 51333-22-3 63006 5281004
21
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2 1959-05-2, 59-05-2 126941
22
Metronidazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 443-48-1 4173
23
Midazolam Approved, Illicit Phase 4,Phase 2 59467-70-8 4192
24
Ciprofloxacin Approved, Investigational Phase 4,Phase 3,Phase 2 85721-33-1 2764
25
Ibuprofen Approved Phase 4,Phase 3 15687-27-1 3672
26
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 73590-58-6 4594
27
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 161796-78-7, 119141-88-7 4594 9579578
28
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
29
Diclofenac Approved, Vet_approved Phase 4,Phase 3 15307-86-5 3033
30
Lansoprazole Approved, Investigational Phase 4,Phase 2 103577-45-3 3883
31
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
32
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 6857599, 9887054 43805
33
Metformin Approved Phase 4,Phase 2 657-24-9 14219 4091
34
Ticlopidine Approved Phase 4 55142-85-3 5472
35
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2 26787-78-0 33613 2171
36
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 564-25-0 54671203
37
Aminosalicylic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1 65-49-6 4649
38
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
39
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-02-2 5743
40
Epirubicin Approved Phase 4,Phase 3,Phase 2 56420-45-2 41867
41
Etoposide Approved Phase 4,Phase 2,Phase 1 33419-42-0 36462
42
Ifosfamide Approved Phase 4,Phase 2 3778-73-2 3690
43
Vincristine Approved, Investigational Phase 4,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
44
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 1 23214-92-8 31703
45
Azithromycin Approved Phase 4 83905-01-5 55185 53477736 447043
46
Etidronic acid Approved Phase 4 7414-83-7, 2809-21-4 3305
47
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 189261-10-7
48
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1 7439-89-6 23925
49
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
50
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2 2078-54-8 4943

Interventional clinical trials:

(show top 50) (show all 1798)
id Name Status NCT ID Phase
1 A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Unknown status NCT01632462 Phase 4
2 Use of Combined Measurements of Serum Infliximab and Anti-infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy Unknown status NCT00851565 Phase 4
3 The Effect of Probiotics on Exacerbation of Inflammatory Bowel Disease Exacerbation (Crohn's Disease) Unknown status NCT01765998 Phase 4
4 Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis Unknown status NCT00513552 Phase 4
5 Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Unknown status NCT00265772 Phase 4
6 Evaluation of PET CT in the Management of Patients With Crohn's Disease. Unknown status NCT00731809 Phase 4
7 Effects of Enteral Nutrition and Corticosteroid on Intestinal Flora in Induction Remission of Crohn Disease in Adult Unknown status NCT02056418 Phase 4
8 Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease Unknown status NCT00609752 Phase 4
9 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease Unknown status NCT02010762 Phase 4
10 VSL#3 Treatment in Children With Crohn's Disease Unknown status NCT00367705 Phase 4
11 Discontinuation of Infliximab Therapy in Patients With Crohn's Disease During Sustained Complete Remission Unknown status NCT01817426 Phase 4
12 Optimizing Cimzia in Crohn's Patients Unknown status NCT01024647 Phase 4
13 Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy Unknown status NCT01698307 Phase 4
14 The Effect of Probiotics on the Rate of Recovery of Inflammatory Bowel Disease Exacerbation, Endothelial Function, and Markers of Inflammation Unknown status NCT01078935 Phase 4
15 "Efficacy and Safety of Infliximab-biosimilar (Inflectra) Compared to Infliximab-innovator (Remicade) in Patients With Inflammatory Bowel Disease in Remission: the SIMILAR Trial" Unknown status NCT02452151 Phase 4
16 Confocal Endomicroscopy During Endoscopy Unknown status NCT00988273 Phase 4
17 Manipulation of Visceral Sensitivity and Immune System in IBS Unknown status NCT00418340 Phase 4
18 The Risk of Bleeding After Removal of Large Colorectal Polyps in Patients Taking Aspirin Unknown status NCT01549418 Phase 4
19 Clinical Management of Childhood Intestinal Lymphoid Nodular Hyperplasia Unknown status NCT01789294 Phase 4
20 Rifaximin Predicts the Complications of Decompensated Cirrhosis Unknown status NCT02074280 Phase 4
21 ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis With High Potency Sucralfate - ProThelial Unknown status NCT02016807 Phase 4
22 Effect of COX-2 Selective Inhibitors on Postoperative Insulin Resistance After Gastrointestinal Laparoscopic Surgery Unknown status NCT01930318 Phase 4
23 Diagnostic Accuracy of Capsule Endoscopy in Small Bowel Crohn's Disease Completed NCT00588653 Phase 4
24 Trial of a Treatment Algorithm for the Management of Crohn's Disease Completed NCT01030809 Phase 4
25 Efficacy Study of Pneumococcal Vaccination in Crohn's Disease Completed NCT01505855 Phase 4
26 A Study Comparing the Acceptability of Pentasa® Sachets Versus Pentasa® Tablets in Children With Crohn´s Disease Completed NCT00225810 Phase 4
27 SECOND GENERATION COLON CAPSULE ENDOSCOPY (CCE-2) IN PEDIATRIC CROHN'S DISEASE (CD). Completed NCT02199626 Phase 4
28 VSL#3 Versus Placebo in Maintenance of Remission in Crohn's Disease Completed NCT00114465 Phase 4
29 Rapidity of Response to Adalimumab Treatment in Patients With Crohn´s Disease Completed NCT02148718 Phase 4
30 Evaluation of the Applicability of the CDEIS to Data Obtained by the Colonic Capsule Endoscopy in Crohn Disease Completed NCT01183845 Phase 4
31 Endoscopic Severity Score of Small Bowel Crohn's Disease With Wireless Capsule Endoscopy Completed NCT00492791 Phase 4
32 Top Down Versus Step Up Strategies in Crohn's Disease Completed NCT00554710 Phase 4
33 The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy Completed NCT01181765 Phase 4
34 Infliximab for the Prevention of Recurrent Crohn's Disease After Surgery Completed NCT00688636 Phase 4
35 The Crohn's Therapy, Resource, Evaluation, and Assessment Tool Registry Completed NCT00553176 Phase 4
36 Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease Completed NCT01596894 Phase 4
37 Adalimumab-psoriasis and Small Bowel Lesions Completed NCT01556672 Phase 4
38 Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease Completed NCT01215890 Phase 4
39 Vitamin D Supplementation in Adult Crohn's Disease Completed NCT01369667 Phase 4
40 Study Investigating Tailored Treatment With Infliximab for Active Crohn's Disease Completed NCT01442025 Phase 4
41 Early Immunosuppressants in Crohn's Disease Completed NCT00546546 Phase 4
42 Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease Completed NCT00280956 Phase 4
43 Endoscopic Detection of Dysplasia in Crohn 's Disease Patient Completed NCT01180452 Phase 4
44 The Effect of Vitamin K Supplementation on Bone Health in Adult Crohn's Disease Patients Completed NCT01235325 Phase 4
45 Vitamin D in Pediatric Crohn's Disease Completed NCT01187459 Phase 4
46 Immune Modulation by Parenteral Fish Oil in Patients With Crohn's Disease Completed NCT02349594 Phase 4
47 An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease. Completed NCT00440817 Phase 4
48 Pneumococcal Vaccination of Crohn Patients Completed NCT01947010 Phase 4
49 Vitd and Barrier Function in IBD Completed NCT01792388 Phase 4
50 Post Marketing Surveillance of Remicade Completed NCT00724529 Phase 4

Search NIH Clinical Center for Inflammatory Bowel Disease 1

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Genetic Tests for Inflammatory Bowel Disease 1

Genetic tests related to Inflammatory Bowel Disease 1:

id Genetic test Affiliating Genes
1 Inflammatory Bowel Disease 1 29

Anatomical Context for Inflammatory Bowel Disease 1

MalaCards organs/tissues related to Inflammatory Bowel Disease 1:

39
Skin, Eye, Colon

Publications for Inflammatory Bowel Disease 1

Articles related to Inflammatory Bowel Disease 1:

id Title Authors Year
1
The mouse and human IGSF6 (DORA) genes map to the inflammatory bowel disease 1 locus and are embedded in an intron of a gene of unknown function. ( 11132146 )
2000
2
Inflammatory bowel disease. 1: Aetiology and pathogenesis. ( 10670307 )
1999
3
Inflammatory bowel disease. 1. Origins, presentation, and course. ( 9590987 )
1998
4
Inflammatory bowel disease (1) ( 1881418 )
1991

Variations for Inflammatory Bowel Disease 1

UniProtKB/Swiss-Prot genetic disease variations for Inflammatory Bowel Disease 1:

66
id Symbol AA change Variation ID SNP ID
1 NOD2 p.Arg702Trp VAR_012689 rs2066844
2 NOD2 p.Gly908Arg VAR_012701 rs2066845

ClinVar genetic disease variations for Inflammatory Bowel Disease 1:

6
id Gene Variation Type Significance SNP ID Assembly Location
1 NOD2 NM_022162.2(NOD2): c.2798+158C> T single nucleotide variant Pathogenic,risk factor rs5743289 GRCh37 Chromosome 16, 50756774: 50756774

Expression for Inflammatory Bowel Disease 1

Search GEO for disease gene expression data for Inflammatory Bowel Disease 1.

Pathways for Inflammatory Bowel Disease 1

Pathways related to Inflammatory Bowel Disease 1 according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 11.14 IL6 NOD1
2 10.97 NOD1 NOD2
3 10.57 NOD1 NOD2
4 10.19 NOD1 NOD2

GO Terms for Inflammatory Bowel Disease 1

Biological processes related to Inflammatory Bowel Disease 1 according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.69 IL6 NOD1 NOD2
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.65 IL6 NOD1 NOD2
3 defense response to Gram-positive bacterium GO:0050830 9.58 IL6 NOD1
4 protein oligomerization GO:0051259 9.58 NOD1 NOD2
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.58 IL6 NOD1 NOD2
6 positive regulation of JNK cascade GO:0046330 9.57 NOD1 NOD2
7 positive regulation of B cell activation GO:0050871 9.56 IL6 NOD2
8 positive regulation of epithelial cell proliferation GO:0050679 9.55 IL6 NOD2
9 JNK cascade GO:0007254 9.54 NOD1 NOD2
10 positive regulation of tumor necrosis factor production GO:0032760 9.52 NOD1 NOD2
11 nucleotide-binding oligomerization domain containing signaling pathway GO:0070423 9.49 NOD1 NOD2
12 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.46 NOD1 NOD2
13 positive regulation of stress-activated MAPK cascade GO:0032874 9.43 NOD1 NOD2
14 positive regulation of interleukin-1 beta production GO:0032731 9.37 NOD1 NOD2
15 detection of bacterium GO:0016045 9.32 NOD1 NOD2
16 positive regulation of dendritic cell antigen processing and presentation GO:0002606 9.26 NOD1 NOD2
17 cellular response to muramyl dipeptide GO:0071225 9.16 NOD1 NOD2
18 detection of biotic stimulus GO:0009595 8.96 NOD1 NOD2
19 positive regulation of interleukin-6 production GO:0032755 8.8 IL6 NOD1 NOD2

Molecular functions related to Inflammatory Bowel Disease 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peptidoglycan binding GO:0042834 8.96 NOD1 NOD2
2 CARD domain binding GO:0050700 8.62 NOD1 NOD2

Sources for Inflammatory Bowel Disease 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....